Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Bexobrutideg

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nurix Reports Updated Phase 1a/b Bexobrutideg Data in CLL/SLL
    Nurix Reports Updated Phase 1a/b Bexobrutideg Data in CLL/SLL

    11 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/11/3310331/0/en/nurix-therapeutics-to-report-updated-phase-1a-b-results-for-btk-degrader-bexobrutideg-highlighting-durable-responses-in-relapsed-refractory-cll-sll-and-promising-activity-in-earlie.html

    GLOBENEWSWIRE
    11 Jun 2026
    Share Share
    Roche Invests $3B In Nurix's Blood Cancer Protein Degrader
    Roche Invests $3B In Nurix's Blood Cancer Protein Degrader

    08 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/08/3307778/0/en/roche-announces-global-collaboration-with-nurix-therapeutics-to-co-develop-and-co-commercialise-potential-best-in-class-btk-degrader-bexobrutideg-across-malignant-haematology-immun.html

    GLOBENEWSWIRE
    08 Jun 2026
    Share Share
    Nurix Presents Bexobrutideg Phase 1 Data at SID 2026
    Nurix Presents Bexobrutideg Phase 1 Data at SID 2026

    14 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/14/3295365/0/en/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-de.html

    GLOBENEWSWIRE
    14 May 2026
    Share Share
    Nurix Therapeutics Presents Bexobrutideg At 2026 EHA Congress
    Nurix Therapeutics Presents Bexobrutideg At 2026 EHA Congress

    12 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/12/3293370/0/en/nurix-therapeutics-announces-bexobrutideg-oral-presentation-at-the-2026-european-hematology-association-congress.html

    GLOBENEWSWIRE
    12 May 2026
    Share Share
    Nurix Therapeutics Releases Q1 2026 Results and Updates
    Nurix Therapeutics Releases Q1 2026 Results and Updates

    08 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/08/3269913/0/en/Nurix-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    08 Apr 2026
    Share Share
    Nurix Therapeutics Reveals 2025 Financials And Corporate Update
    Nurix Therapeutics Reveals 2025 Financials And Corporate Update

    28 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/28/3228040/0/en/Nurix-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    28 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.